Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 333

1.

Superior Rhythm Discrimination With the SmartShock Technology Algorithm - Results of the Implantable Defibrillator With Enhanced Features and Settings for Reduction of Inaccurate Detection (DEFENSE) Trial.

Oginosawa Y, Kohno R, Honda T, Kikuchi K, Nozoe M, Uchida T, Minamiguchi H, Sonoda K, Ogawa M, Ideguchi T, Kizaki Y, Nakamura T, Oba K, Higa S, Yoshida K, Tsunoda S, Fujino Y, Abe H.

Circ J. 2017 Apr 20. doi: 10.1253/circj.CJ-16-1330. [Epub ahead of print]

2.

Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial).

Kotake M, Aoyama T, Munemoto Y, Doden K, Kataoka M, Kobayashi K, Nishimura G, Fujita H, Nakamura K, Takehara A, Tanaka C, Sakamoto J, Nagata N, Oba K, Kondo K.

Oncol Lett. 2017 Feb;13(2):747-753. doi: 10.3892/ol.2016.5505. Epub 2016 Dec 14.

3.

Comprehensive pathogen detection associated with four recurrent episodes of Kawasaki disease in a patient during a single year using next-generation sequencing.

Hamada H, Sekizuka T, Oba K, Katano H, Kinumaki A, Terai M, Mizutani T, Kuroda M.

JMM Case Rep. 2016 Feb 1;3(1):e005019. doi: 10.1099/jmmcr.0.005019. eCollection 2016 Feb.

4.

Epithelioid cell granuloma in the bone marrow secondary to Epstein-Barr virus infection.

Mori N, Ohya H, Oba K, Shiraishii J.

Lancet Infect Dis. 2017 Apr;17(4):460. doi: 10.1016/S1473-3099(16)30520-5. No abstract available.

PMID:
28346186
5.

Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients.

Ishiguro N, Koseki N, Kaiho M, Ariga T, Kikuta H, Togashi T, Oba K, Morita K, Nagano N, Nakanishi M, Hara K, Hazama K, Watanabe T, Yamanaka T, Sasaki S, Furuyama H, Shibata M, Shida S, Ishizaka A, Tabata Y, Aoyagi H, Naito H, Yoshioka M, Horino A, Kenri T; Hokkaido Pediatric Respiratory Infection Study Group..

PLoS One. 2017 Mar 13;12(3):e0173635. doi: 10.1371/journal.pone.0173635. eCollection 2017.

6.
7.

Identification of candidate diagnostic serum biomarkers for Kawasaki disease using proteomic analysis.

Kimura Y, Yanagimachi M, Ino Y, Aketagawa M, Matsuo M, Okayama A, Shimizu H, Oba K, Morioka I, Imagawa T, Kaneko T, Yokota S, Hirano H, Mori M.

Sci Rep. 2017 Mar 6;7:43732. doi: 10.1038/srep43732.

8.

Relationship between pre-anesthetic and intra-anesthetic airway resistance in patients undergoing general anesthesia: A prospective observational study.

Ikeda T, Uchida K, Yamauchi Y, Nagase T, Oba K, Yamada Y.

PLoS One. 2017 Feb 17;12(2):e0172421. doi: 10.1371/journal.pone.0172421. eCollection 2017.

9.

Cementless calcar-replacement stem with integrated greater trochanter plate for unstable intertrochanteric fracture in very elderly patients.

Wada K, Mikami H, Oba K, Yonezu H, Sairyo K.

J Orthop Surg (Hong Kong). 2017 Jan;25(1):2309499016684749. doi: 10.1177/2309499016684749.

10.

Safety of laparoscopic surgery for colorectal cancer in patients over 80 years old: a propensity score matching study.

Shiga M, Maeda H, Oba K, Okamoto K, Namikawa T, Fujisawa K, Yokota K, Kobayashi M, Hanazaki K.

Surg Today. 2017 Jan 27. doi: 10.1007/s00595-017-1470-5. [Epub ahead of print]

PMID:
28130643
11.

Two-by-two cross-over study to evaluate agreement between versions of a quantitative coronary analysis system (QAngio XA).

Kozuma K, Kashiwabara K, Shinozaki T, Kozuma K, Oba K, Matsuyama Y.

Int J Cardiovasc Imaging. 2017 Jun;33(6):779-787. doi: 10.1007/s10554-017-1068-4. Epub 2017 Jan 21.

PMID:
28110432
12.

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study).

Nakamura M, Aoyama T, Ishibashi K, Tsuji A, Takinishi Y, Shindo Y, Sakamoto J, Oba K, Mishima H.

Cancer Chemother Pharmacol. 2017 Jan;79(1):29-36. doi: 10.1007/s00280-016-3203-7. Epub 2016 Nov 22.

13.

Relationship between daily and day-to-day glycemic variability and increased oxidative stress in type 2 diabetes.

Ohara M, Fukui T, Ouchi M, Watanabe K, Suzuki T, Yamamoto S, Yamamoto T, Hayashi T, Oba K, Hirano T.

Diabetes Res Clin Pract. 2016 Dec;122:62-70. doi: 10.1016/j.diabres.2016.09.025. Epub 2016 Oct 14.

14.

Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial.

Denda T, Kanda M, Morita Y, Kim HM, Kashiwada T, Matsuda C, Fujieda S, Nakata K, Murotani K, Oba K, Sakamoto J, Mishima H.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1253-1261. Epub 2016 Nov 2.

PMID:
27807652
15.

Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer.

Watanabe T, Ajioka Y, Mitsuyama K, Watanabe K, Hanai H, Nakase H, Kunisaki R, Matsuda K, Iwakiri R, Hida N, Tanaka S, Takeuchi Y, Ohtsuka K, Murakami K, Kobayashi K, Iwao Y, Nagahori M, Iizuka B, Hata K, Igarashi M, Hirata I, Kudo SE, Matsumoto T, Ueno F, Watanabe G, Ikegami M, Ito Y, Oba K, Inoue E, Tomotsugu N, Takebayashi T, Sugihara K, Suzuki Y, Watanabe M, Hibi T.

Gastroenterology. 2016 Dec;151(6):1122-1130. doi: 10.1053/j.gastro.2016.08.002. Epub 2016 Aug 12.

16.

Estimating individual optimal sleep duration and potential sleep debt.

Kitamura S, Katayose Y, Nakazaki K, Motomura Y, Oba K, Katsunuma R, Terasawa Y, Enomoto M, Moriguchi Y, Hida A, Mishima K.

Sci Rep. 2016 Oct 24;6:35812. doi: 10.1038/srep35812.

17.

A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1).

Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Inoue A, Atsumi T, Manda N, Kurihara Y, Aoki S; SAIS Study Group..

PLoS One. 2016 Oct 6;11(10):e0164255. doi: 10.1371/journal.pone.0164255. eCollection 2016.

18.

Erratum to: The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.

Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):1064. No abstract available.

PMID:
27646021
19.

The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.

Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K.

Ann Surg Oncol. 2017 Feb;24(2):546-553. doi: 10.1245/s10434-016-5557-9. Epub 2016 Sep 8. Erratum in: Ann Surg Oncol. 2016 Dec;23 (Suppl 5):1064.

PMID:
27638675
20.

A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study).

Hazama S, Maeda H, Iwamoto S, Kim HM, Takemoto H, Kobayashi K, Sakamoto J, Nagata N, Oba K, Mishima H.

Clin Colorectal Cancer. 2016 Dec;15(4):329-336. doi: 10.1016/j.clcc.2016.07.003. Epub 2016 Jul 18.

PMID:
27507128

Supplemental Content

Loading ...
Support Center